These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma. Ozgen M; Koca SS; Isik A; Ozercan IH J Rheumatol; 2010 Mar; 37(3):678-9. PubMed ID: 20197571 [No Abstract] [Full Text] [Related]
3. SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice. Kimura M; Kawahito Y; Hamaguchi M; Nakamura T; Okamoto M; Matsumoto Y; Endo H; Yamamoto A; Ishino H; Wada M; Omoto A; Tsubouchi Y; Kohno M; Yoshikawa T Biomed Pharmacother; 2007 May; 61(4):222-8. PubMed ID: 17147981 [TBL] [Abstract][Full Text] [Related]
4. Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. Karatas A; Celik C; Oz B; Akar ZA; Etem EO; Dagli AF; Koca SS Int J Rheum Dis; 2021 Jun; 24(6):795-802. PubMed ID: 33835703 [TBL] [Abstract][Full Text] [Related]
5. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin. Ohashi T; Yamamoto T Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255 [TBL] [Abstract][Full Text] [Related]
6. Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma. Park GT; Kwon YW; Lee TW; Kwon SG; Ko HC; Kim MB; Kim JH Front Immunol; 2019; 10():2095. PubMed ID: 31552041 [TBL] [Abstract][Full Text] [Related]
7. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Yamamoto T; Kuroda M; Nishioka K Arch Dermatol Res; 2000 Nov; 292(11):535-41. PubMed ID: 11194891 [TBL] [Abstract][Full Text] [Related]
8. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Yoshizaki A; Yanaba K; Ogawa A; Iwata Y; Ogawa F; Takenaka M; Shimizu K; Asano Y; Kadono T; Sato S Arthritis Rheum; 2011 Oct; 63(10):3086-97. PubMed ID: 21618208 [TBL] [Abstract][Full Text] [Related]
9. UVA irradiation following treatment with topical 8-methoxypsoralen improves bleomycin-induced scleroderma in a mouse model, by reducing the collagen content and collagen gene expression levels in the skin. Hayashi S; Ikeda M; Kitamura Y; Hamasaki Y; Hatamochi A J Dermatol Sci; 2012 Jul; 67(1):20-5. PubMed ID: 22486844 [TBL] [Abstract][Full Text] [Related]
10. Effect of interferon-gamma on experimental scleroderma induced by bleomycin. Yamamoto T; Takagawa S; Kuroda M; Nishioka K Arch Dermatol Res; 2000 Jul; 292(7):362-5. PubMed ID: 10966061 [No Abstract] [Full Text] [Related]
11. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. Yamamoto T; Takagawa S; Katayama I; Yamazaki K; Hamazaki Y; Shinkai H; Nishioka K J Invest Dermatol; 1999 Apr; 112(4):456-62. PubMed ID: 10201529 [TBL] [Abstract][Full Text] [Related]
12. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. Ishikawa H; Takeda K; Okamoto A; Matsuo S; Isobe K J Invest Dermatol; 2009 Jul; 129(7):1688-95. PubMed ID: 19158840 [TBL] [Abstract][Full Text] [Related]
13. Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway. Zhu X; Chu H; Jiang S; Liu Q; Liu L; Xue Y; Zheng S; Wan W; Qiu J; Wang J; Zou H J Dermatol Sci; 2017 Aug; 87(2):149-158. PubMed ID: 28532580 [TBL] [Abstract][Full Text] [Related]